The ENO3 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout population derived from Raji B lymphocytes, designed to disrupt the ENO3 gene and eliminate beta-enolase expression. This mixed pool of edited cells circumvents clonal artifacts, providing a physiologically relevant loss-of-function model. It serves as a versatile platform for investigating enolase function in lymphocyte biology, metabolic regulation, and disease-related processes.
Raji is an EBV-positive Burkitt??s lymphoma B-cell line extensively used to model humoral immunity, lymphomagenesis, and oncogenic signaling. These suspension cells retain key features of activated B lymphocytes and are highly glycolytic, mirroring the Warburg effect prevalent in many cancers. Their well-characterized background makes them an ideal host for studying metabolic reprogramming and the impact of EN03 disruption on B-cell physiology.
ENO3 encodes beta-enolase, which catalyzes the penultimate glycolytic step, converting 2-phosphoglycerate to phosphoenolpyruvate, a critical reaction linking carbon flux to ATP generation and pyruvate kinase activity. Beyond its enzymatic role, ENO3 acts as a plasminogen receptor, interacting with actin and tubulin to regulate cell migration and invasion. ENO3 expression is transcriptionally governed by MEF2, MyoD, and the hypoxia-responsive HIF1A, integrating developmental and metabolic signals. Disruption of ENO3 halts glycolytic conversion of 2-phosphoglycerate, diminishing phosphoenolpyruvate production, curtailing downstream pyruvate and ATP synthesis, and perturbing metabolic flux. Additionally, loss of plasminogen-binding capacity may impair extracellular matrix interactions and cytoskeletal dynamics.
In Raji B lymphocytes, which rely on aerobic glycolysis for proliferation and effector functions, ENO3 knockout imposes a metabolic bottleneck that limits energy production and biosynthetic pathways. The resulting metabolic stress likely affects antibody production, immune synapse formation, and EBV-driven growth. This model thus enables dissection of glycolysis-dependent processes in B-cell malignancies and immune responses, while the abrogation of non-glycolytic functions offers insight into enolase-mediated cell migration and adhesion. The polyclonal nature preserves cellular heterogeneity, making it suitable for studying population-level metabolic adaptations.
Research applications include cancer metabolism studies, glycolysis inhibition profiling, investigation of enolase function in lymphocytes, and drug target validation. Key assays encompass Western blotting for ENO3, glycolytic flux analysis, ATP quantification, cell viability assessments under metabolic stress, migration assays, and Seahorse metabolic analysis. This polyclonal knockout population enables functional interrogation of ENO3-dependent pathways, evaluation of small-molecule enolase inhibitors, and exploration of synthetic lethal interactions. For further product details, please contact Ascent Research.
